In this study, a serotype-specific monoclonal antibody (mAb), D 2 16-1 (Ab4), against dengue virus type 2 (DEN-2) was generated. The specificity of Ab4, which recognized DEN-2 non-structural protein 1, was determined by ELISA, immunofluorescence and immunoblotting analyses. The serotype-specific B-cell epitope of Ab4 was identified further from a random phage-displayed peptide library; selected phage clones reacted specifically with Ab4 and did not react with other mAbs. Immunopositive phage clones displayed a consensus motif, His-Arg/Lys-Leu/Ile, and a synthetic peptide corresponding to the phage-displayed peptide bound specifically to Ab4. The His and Arg residues in this epitope were found to be crucial for peptide binding to Ab4 and binding activity decreased dramatically when these residues were changed to Leu. The epitope-based synthetic peptide not only identified serum samples from DEN-2-immunized mice and rabbits by ELISA but also differentiated clearly between serum samples from DEN-2-and Japanese encephalitis virus-immunized mice. This mAb and its epitope-based peptide antigen will be useful for serologic diagnosis of DEN-2 infection. Furthermore, DEN-2 epitope identification makes it feasible to dissect antibody responses to DEN and to address the role of antibodies in the pathogenesis of primary and secondary DEN-2 infections.
INTRODUCTION
Dengue virus (DEN) is a human pathogen that causes a spectrum of illnesses that range from mild, undifferentiated acute fever to severe syndromes such as dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) (Halstead, 1988; Henchal & Putnak, 1990; Gubler & Clark, 1995) . Primary DEN infection can cause painful, debilitating and non-fatal dengue fever (DF). It appears to protect against re-infection by the same serotype. Severe and sometimes fatal DHF and DSS often occur in regions where more than one DEN serotype is circulating (Halstead, 1988; Gubler, 1998) . A second, different DEN serotype infection has been associated with increased risk for DHF and may be caused by monocyte/macrophage uptake of virus complexes to non-neutralizing antibodies, subneutralizing cross-reactive antibodies or low-titre neutralizing antibodies (Halstead et al., 1984; Halstead, 1988; Bielefeldt-Ohmann, 1997) .
Virus infection triggers production of antibodies directed against viral protein epitopes by activating host humoral immunity. Epitopes can be classified as conformational (discontinuous or linear sequences) or non-conformational (linear sequences) (Sela, 1969; Barlow et al., 1986; Laver et al., 1990) . Linear epitopes are short stretches of primary protein structure composed of continuous amino acid residues of the primary sequence. Conformational epitopes consist of several amino acid residues, discrete in primary sequence, that assemble to form antigenic determinants on the tertiary structure of native proteins (Barlow et al., 1986; Laver et al., 1990) . Viral protein epitopes are pivotal in the pathogenesis of virus infectious diseases and in the development of effective vaccines and diagnostic reagents.
Advances in peptide technology have led to the development of combinatorial peptide libraries expressed on a solid-phase support or displayed on bacteriophages. Phagedisplayed random peptide libraries and the high molecular diversity displayed by these libraries provide opportunities to study various topics: mapping B-cell epitopes (Scott & Smith, 1990; D'Mello et al., 1997; Fu et al., 1997; Wu et al., 2001a, b) and protein-protein contacts (Atwell et al., 1997; Bottger et al., 1997; Nord et al., 1997; Smith et al., 1999) , selecting bioactive peptides bound to receptors (Li et al., 1995; Akeson et al., 1996; Wrighton et al., 1996; Koivunen et al., 1999) or proteins (Castano et al., 1995; Pasqualini et al., 1995; DeLeo et al., 1995; Bottger et al., 1996; Kraft et al., 1999) , searching for disease-specific antigen mimics (Folgori et al., 1994; Prezzi et al., 1996) , determining cell- (Barry et al., 1996; Szardenings et al., 1997; Mazzucchelli et al., 1999) and organ-specific peptides (Pasqualini & Ruoslahti, 1996; Arap et al., 1998 Arap et al., , 2002 Rajotte & Ruoslahti, 1999; Essler & Ruoslahti, 2002) , producing peptides that mimic the effect of neutralizing antibodies (Heiskanen et al., 1997) and identifying peptides that mimic non-peptide ligands .
DEN is a major cause of paediatric morbidity and mortality in tropical regions (Halstead, 1988) . A safe vaccine and simple reliable test for serodiagnosis of DEN infection could reduce morbidity and mortality significantly. Serotypespecific B-cell epitopes of DEN are not well documented. Currently, neither a protein nor a peptide antigen has been used to differentiate the four DEN serotypes.
Recently, we identified the serotype-specific B-cell epitope of DEN-1 (Wu et al., 2001a) . In this study, we generated a serotype-specific mAb against DEN-2 and used a phagedisplayed peptide library to identify the serotype-specific B-cell epitope for DEN-2. This serotype-specific mAb and epitope-based peptide can be used to develop a convenient, efficient serologic test that identifies DEN serotypes.
METHODS
Cells and viruses. DEN-2 strain PL046, a local Taiwanese strain isolated from patients with DF in Hsiao-Liu-Chiu (Islet of Pingtung, Taiwan, Republic of China) was provided by the National Institute of Preventive Medicine, Taiwan, Republic of China. Four prototype DEN strains [DEN-1 (Hawaii), DEN-2 (New Guinea C), DEN-3 (H87) and DEN-4 (H241)] were provided by D. J. Gubler (Centers for Disease Control and Prevention, Fort Collins, USA). These viruses were passaged in Aedes albopictus C6/36 cells and DEN titres were measured by plaque assay in BHK-21 cells. C6/36 cells were grown in RPMI 1640 medium containing 10 % heat-inactivated FBS. BHK-21 cells were grown in RPMI 1640 medium containing 5 % heat-inactivated FBS.
Generation of serotype-specific mAbs against DEN-2.
Hybridomas secreting anti-DEN-2 antibodies were generated according to standard procedures (Kohler & Milstein, 1975) . Briefly, the spleen of an immunized mouse was removed. Splenocytes were fused with NSI/1-Ab4-1 (NS-1) myeloma cells and washed twice with DMEM. Fused cells were then mixed in a 15 ml conical tube and 1 ml 50 % (v/v) PEG (Gibco-BRL) was added over 1 min with gentle stirring. The mixture was diluted by the slow (1 min) addition of 1 ml DMEM, twice, followed by the slow addition (2 min) of 8 ml serum-free DMEM. The mixture was then centrifuged at 400 g for 5 min. The fused cell pellet was re-suspended in DMEM supplemented with 15 % FBS, HAT medium and hybridoma cloning factor (ICN). Next, 150 ml per well of the resuspension mixture was distributed in 96-well tissue culture plates. Hybridoma colonies were screened by ELISA for mAbs that bound DEN-infected C6/36 cells. Selected clones were subcloned by limiting dilution. Final hybridoma clones were isotyped using an isotyping kit from Roche Diagnostics. Ascites fluids were produced in pristane-primed BALB/c mice.
Hybridoma cell lines were grown in RPMI 1640 medium with 10 % heat-inactivated FBS. mAbs were affinity-purified using a protein G-Sepharose 4B gel and ELISA and Western blot assays were used to measure the activity and specificity of the antibodies isolated.
Preparation of DEN-2 antigen. C6/36 cells were infected with DEN-2, pelleted and washed three times with PBS. Cells were then lysed in lysis buffer (25 mM Tris/HCl, pH 7?4, 150 mM NaCl and 1 % Nonidet-P40) in the presence of protease inhibitors (1 mM EDTA, 0?1 mM PMSF, 10 mM leupeptin, 10 mM chymostatin and 1 mM pepstatin). Cell debris was removed by centrifugation at 3000 g for 10 min at 4 uC and protein was quantified using the protein dye-binding method described by Bradford (1976) .
Western blot analysis. Cell lysates or proteins were mixed with an equal volume of sample buffer (50 mM Tris/HCl, pH 6?8, 100 mM DTT, 2 % SDS, 0?1 % bromophenol blue and 10 % glycerol), separated by SDS-PAGE and then transferred to a nitrocellulose membrane (Hybond-C Super, Amersham). Non-specific antibody-binding sites were blocked with 5 % skimmed milk in PBS and membranes were incubated with primary antibody. Blots were then treated with HRP-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) and developed with chemiluminescence reagents (ECL, Amersham). Phage-display biopanning procedures. An ELISA plate was coated with 100 mg mAb Ab4 ml 21 in 0?1 M NaHCO 3 (pH 8?6) buffer: samples of 100 ml of diluted mAb were then added to each well and incubated at room temperature for 2 h with gentle agitation. The plate was washed, incubated with blocking buffer (1 % BSA in PBS) at 4 uC overnight and then washed rapidly five times with PBST. The phage-displayed peptide library was diluted to 4610 10 phage, added onto the coated plate and rocked gently for 50 min at room temperature. The plate was then washed 10 times with PBST. Bound phage was eluted with 100 ml 0?2 M glycine/HCl (pH 2?2) and 1 mg BSA ml 21 and the eluate was neutralized with 15 ml 1 M Tris/HCl (pH 9?1). Eluted phage was amplified in ER2738 culture at 37 uC with vigorous shaking for 4?5 h. Amplified phage was centrifuged for 20 min at 10 000 g at 4 uC and supernatant was removed to a fresh tube and re-spun. The upper 80 % of the supernatant was removed to a fresh tube and 1/6 vol. PEG/NaCl [20 % (w/v) PEG-8000 and 2?5 M NaCl] was added to precipitate the phage at 4 uC overnight. Phage was isolated by centrifugation for 20 min at 10 000 g at 4 uC. The phage pellet was suspended in 1 ml PBS and centrifuged for 5 min at 4 uC to pellet residual cells. The supernatant was transferred to a fresh microcentrifuge tube and reprecipitated with 1/6 vol. PEG/NaCl on ice for 45 min. Phage was isolated by centrifugation at 4 uC for 10 min and re-suspended in 200 ml PBS containing 0?02 % NaN 3 . Isolated phage was centrifuged for 1 min to pellet any remaining insoluble matter. The supernatant was transferred to a fresh tube and amplified phage was titrated onto LB medium plates containing IPTG and X-Gal. The protocol for second-round biopanning was identical to the first, with the addition of 2610 11 p.f.u. from first-round biopanning phage to each well. Third-round biopanning was, once again, identical to the first, with the addition of 2610 11 p.f.u. of second-round biopanning phage to each well. Unamplified third-round phage eluate was titrated on LB medium plates containing IPTG and X-Gal. The remaining eluate was stored at 4 uC.
Identification of immunopositive phage clones by ELISA. An ELISA plate was coated with 100 ml antibody (100 mg ml 21 ) in 0?1 M NaHCO 3 (pH 8?6) at room temperature for 2 h and blocked with blocking buffer at 4 uC overnight. Serially diluted phage was added to the antibody-coated plate and incubated at room temperature for 1 h. The plate was then washed six times with PBST and diluted HRP-conjugated anti-M13 antibody (Pharmacia) diluted 1 : 5000 in blocking buffer was added. The plate was incubated at room temperature for 1 h with agitation and washed six times with PBST. HRP/substrate solution was added to each well and incubated at room temperature. The reaction was stopped with 3 N HCl and the plate was read using a microplate reader set at a wavelength of 490 nm.
DNA sequencing and computer analysis. DNA sequences of purified phage were determined according to the dideoxynucleotide chain termination method using an automated DNA sequencer (ABI PRISM 377, Perkin-Elmer). The primer used for phage DNA sequencing was 59-CCCTCATAGTTAGCGTAA-39; this primer locates to the antisense strand of gene III of the M13 phage and is 96 nt away from the inserted DNA. Inserted oligonucleotide sequences of phage DNA were selected and translated to peptide sequences. Peptide sequences were aligned using the DNASIS software designed for the Apple Macintosh (Hitachi Software Engineering).
Antibody-binding assay. ELISA plates were coated with 50 ml per well of individual peptide antigens at a concentration of 10 mg ml 21 and blocked with 1 % BSA. For the binding assay, 2-fold serial peptide antigens (concentrations ranging from 20 to 0?31 mg ml 21 ) were coated to the plates and 2 mg antibody ml 21 was added to each well and incubated at room temperature for 1 h. Plates were incubated with HRP-conjugated anti-mouse IgG and colour was subsequently developed with o-phenylenediamine dihydrochloride (Sigma) and hydrogen peroxide in the dark. The reaction was stopped with 3 N HCl and the absorbance was measured at 490 nm.
Animal immunization. Female, 4-to 6-week-old, BALB/c mice were immunized by intraperitoneal (i.p.) injection of DEN and Japanese encephalitis virus (JEV) with adjuvant on days 0, 14 and 28; mice were bled on day 38. Outbreed laboratory rabbits were infected by intravenous (i.v.) injection with DEN-2. Serum samples used in IgM assays were collected 7 days after an initial i.v. infection. Hyperimmune sera were obtained following four inoculations with virus. Immunized serum samples of mice and rabbits were collected and antibody levels were measured by ELISA.
RESULTS

Identification of serotype-specific mAbs against DEN-2
Immunoblotting and ELISA assays determined the reactivity of mAb D 2 16-1 (Ab4) with DEN-2 and other DEN serotypes. Ab4 reacted only to NS1 of DEN-2 and did not cross-react with DEN-1, -3 or -4 (Fig. 1) . Immunoblotting analysis showed that the NS1 protein of DEN-2 was dimeric on a native gel (Fig. 1A, NS1 2 ) and monomeric on a denaturing gel (Fig. 1B, NS1) . ELISA confirmed the specificity of Ab4. C6/36 cells were infected with DEN-1, -2, -3 and -4. Cells were then fixed for ELISA analysis using Ab4, normal mouse IgG (NM-IgG) and normal mouse serum (NMS). Ab4 detected DEN-2-infected cells but not DEN-1-, -3-or -4-infected cells (Fig. 1C) . To confirm the DEN-2 serotype-specificity of Ab4, we also performed an indirect immunofluorescence assay. BHK-21 cells were infected with DEN-1, -2, -3 or -4. Only DEN-2-infected BHK-21 cells were detected by Ab4; DEN-1-, -3-and -4-infected cells were not reactive (data not shown). We concluded that Ab4 is a DEN-2 serotype-specific mAb that does not cross-react with other DEN serotypes.
Screening of phage-displayed peptide library with DEN-2 serotype-specific antibody Ab4, a serotype-specific mAb of DEN-2, is an IgG 1 isotype (data not shown). Its B-cell epitope was identified by the phage-display method. To select immunopositive phage clones by DEN-2-specific mAbs, Ab4 ascites fluid was purified by a protein G affinity column. Purified antibodies were immobilized on ELISA plates and bound phage clones were selected after biopanning three times. Further screening of immunopositive phage clones was performed by single phage clone isolation and amplification for Ab4 screening by ELISA. Of the 20 phage clones selected, 17 (Ab4-C1, C2, C3, C4, C5, C6, C7, C8, C11, C12, C13, C14, C15, C17, C18, C19 and C20) had significant enhancement of antibody Ab4 reactivity (Fig. 2) ; they did not bind to either NMS or NM-IgG (Fig. 2) .
To prove that the selected phage clone bound Ab4 specifically, antibodies were incubated with a 10-fold serial dilution of the selected phage clone (Ab4-C4) and the control phage clone (HB47-1, selected by an anti-DEN-1 mAb). Only the selected phage clone (Ab4-C4) bound the antibody specifically and dose dependently. The control phage clone (HB47-1) did not react with the antibody (Fig. 3A) . To confirm further that the selected phage clone Ab4-C4 bound Ab4 specifically, eight (Ab9-1, 12-1, 32-7, 42-1, 43-1, 45-3, 48-6 and 52-2) mAbs against DEN-2 and NM-IgG were incubated with Ab4-C4 and an ELISA was performed. The immunopositive phage clone Ab4-C4 showed high Ab4 antibody specificity and did not react with these eight mAbs or with NM-IgG (Fig. 3B) . The control phage clone (HB47-1) did not bind Ab4 (Fig. 3B) .
Characterization of the B-cell epitope
Twelve immunopositive phage clones (Ab4-C2, C3, C4, C8, C11, C12, C13, C14, C15, C17, C19 and C20) that were highly reactive with Ab4 were amplified and phage DNAs were isolated for DNA sequencing. The sequencing primer, 59-CCCTCATAGTTAGCGTAA-39, is located in the antisense strand of gene III of the M13 phage and has 96 nt separated from the inserted DNA. Inserted nucleotides of the selected phage clones were sequenced. All contained 36 inserted nucleotides (translated to 12 aa residues) ( Table 1) . Inserted oligonucleotide sequences of phage DNAs were selected and translated to peptide sequences. Peptide sequences were aligned using DNASIS to analyse the epitopes and the binding motif of Ab4. Interestingly, three residues, His (H)-Arg (R)/Lys (K)-Leu (L)/Ile (I), were highly conserved in these immunopositive phage clones; the other nine residues were random (Table 1) . We concluded that the binding motif for Ab4 is His-Arg/Lys-Leu/Ile and that all phage clones selected contained this motif (Table 1) .
Binding assay of a mimic synthetic peptide
To verify that peptide sequences identified by phage display were recognized by antibody Ab4, synthetic peptide-binding assays were carried out. Phage-displayed peptides were synthesized in multiple antigen peptide (MAP) form because ELISA sensitivity for an eight-chain MAP is greater than for a single-chain peptide (Tam & Fig. 2 . Identification of Ab4-selected phage clones by ELISA. A phage-displayed random peptide library was screened by Ab4. After three rounds of screening, 17 phage clones from 20 selected phage clones showed significant reactivity to antibody Ab4 but not to normal mouse serum (NMS) or normal mouse IgG. Wu et al., 2001a) . As shown in Fig. 4 , synthetic peptide P7M (SHRLHNTMPSES), corresponding to immunopositive phage clone Ab4-C4 (Table 1) , which had been selected with Ab4 from the phage-displayed peptide library, bound antibody in a concentration-dependent manner. Unrelated control MAP peptides, KGTFDPLQEPRT (P4M) and EHKYSWKS (P14M), were not reactive.
Zavala
Using the phage-display method, we determined that the binding motif for Ab4 was His-Arg-Leu/Ile. His and Arg were found in most immunopositive phage clones (Table 1) . We proposed that these two amino acid residues play a crucial role in binding to the antibody. To prove this hypothesis, we synthesized two peptides: P7M-m1 (SLRLHNTMPSES) and P7M-m2 (SHLLHNTMPSES). There is only a difference of one amino acid residue between these peptides and P7M (SHRLHNTMPSES). ELISA indicated that binding activity was decreased dramatically when positively charged His or Arg in P7M was changed to aliphatic side-chain Leu in P7M-m1 or P7M-m2, respectively (Fig. 5A ). Control peptide P4M (KGTFDPLQEPRT) was not reactive with Ab4 (Fig. 5A ).
To confirm further that the phage-displayed peptide was the epitope of Ab4, a peptide-competitive inhibition assay was performed to determine whether the synthetic peptide P7M competed with NS1 proteins for reactivity with Ab4. The reaction activity of Ab4 with NS1 proteins was inhibited markedly by P7M. The mutated peptide P7M-m1 had no effect on Ab4 reaction with NS1 proteins (Fig. 5B ). Our observations suggest strongly that P7M is the B-cell epitope of Ab4 and that His and Arg are important residues for binding to the mAb.
Detection of DEN-2-infected animal sera using epitope-based synthetic peptides
We evaluated whether the epitope-based peptide antigen P7M could be used as a diagnostic tool to detect immunized The reactivity of Ab4 with NS1 was inhibited by phage-displayed peptide P7M; control peptide P7M-m1 had no effect. Phage-displayed consensus amino acids are shown in bold.
Clone Insert
animal serum samples. Two different species of animals were immunized with DEN-2. Serum samples were collected to test detection efficacy. To test whether antibodies produced from DEN-2-immunized rabbit sera would react with synthetic peptide P7M, we collected hyperimmune serum samples after four inoculations with DEN-2 for ELISA. All serum samples from DEN-2 hyperimmune rabbits had higher ELISA antibody reactivity with P7M peptide than with pre-immune serum samples (Fig. 6B) . Serum samples obtained from five JEV hyperimmune and eight normal BALB/c mice had no significant ELISA reactivity with P7M; however, serum samples from all eight DEN-2 hyperimmune BALB/c mice had significant ELISA reactivity with peptide antigen (Fig. 6A ). This suggests that P7M can differentiate between JEV and DEN-2 in immunized mouse serum samples. Using different animals and different immunization techniques (i.p. inoculation in mice and i.v. inoculation in rabbits), we determined that P7M could identify DEN-2-immunized animal serum samples. To test further the specificity of P7M, we used this peptide antigen to detect DEN-1-, -2-and -3-immunized mouse serum samples. P7M detected all eight DEN-2 hyperimmune BALB/c mice by ELISA (Fig. 6C) . In contrast, all serum samples obtained from DEN-1 and -3 hyperimmune mice were seronegative. These results indicated that vertebrates like rabbits and mice immunized with DEN-2 can produce antibodies recognized by this epitope-based synthetic peptide antigen.
DISCUSSION
The identification of viral B-cell epitopes is important for peptide selection for subunit vaccines, development of virus-specific serological diagnostic reagents and understanding virus-antibody interactions at a molecular level. This is the first study to characterize a serotype-specific B-cell epitope of a DEN-2 mAb using the phage-display method. We found that the selected phage-displayed 12-mer peptide sequence had a consensus motif, His-Arg/Lys-Leu/ Ile. We also detected antibodies from serum samples of DEN-2-immunized animals using the epitope-based peptide antigen. It is feasible that our serotype-specific mAb, phage-displayed epitope and epitope-based peptide antigen can be used to develop diagnostic laboratory tests for serologic DEN identification.
B-cell epitopes of DEN-2 have been documented using overlapping synthetic peptides (PEPSCAN) to analyse antisera (Aaskov et al., 1989; Innis et al., 1989; Roehrig et al., 1990) . However, this approach requires many overlapping synthetic peptides, has difficulty identifying conformational epitopes and cannot determine the amino acid-binding motif. A variety of DEN-2 antigenic domains have been studied by antigen fragments using recombinant or enzyme-cleavage proteins (Mason et al., 1990; Megret et al., 1992; Trirawatanapong et al., 1992; Roehrig et al., 1998) . Even though these methods have identified antigenic domains consisting of 50-200 aa residues, they have not been able to specify an exact epitope consisting of only three to eight amino acids. At present, no serotype-specific B-cell epitope has been identified by any of these methods. Phage display is a powerful tool for analysing linear and conformational epitopes or mimotopes, which are generally difficult to characterize. Using this method, we have identified the serotype-specific B-cell epitope of DEN-1 (Wu et al., 2001a) and neutralizing B-cell epitopes on Clostridium botulinum neurotoxin (Wu et al., 2001b) . In the present study, we isolated the serotype-specific B-cell epitope of DEN-2 and confirmed further that the HisArg-Leu motif was crucial for peptide antigen-antibody binding. In the B-cell DEN-1 epitope study, phage-displayed peptides had a consensus motif of HxYaWb (a=S/T and b=K/H/R). This motif mimics the HKYSWK sequence, which corresponds to aa 111-116 of NS1 of DEN-1 (Wu et al., 2001a) . These findings indicate that the B-cell epitope of this DEN-1 antibody is linear. Typically, B-cell epitopes identified by this method have an easily recognizable consensus sequence, often corresponding to the peptide sequence found in the natural antigen. However, sometimes the phage-displayed consensus sequence cannot be found in the sequence of natural antigens. For example, our present study and earlier published data (Wu et al., 2001b) as well as other reports (Felici et al., 1993; Folgori et al., 1994) have demonstrated that phage-displayed epitopes interact with antigen-binding sites of antibodies. However, consensus sequences may not show any similarity with the sequence of the natural antigen (Felici et al., 1993; Folgori et al., 1994) . In these cases, epitopes can mimic natural epitopes (mimotopes) or conformational epitopes.
Further analysis of the Ab4 epitope indicated that most immunopositive phage clones contained His and Arg (Table 1) . These amino acids may play an important role in antibody binding. To test this hypothesis, we synthesized two peptides corresponding to P7M in which His and Arg were substituted with Leu. Specificity and reactivity of these peptides for Ab4 were determined by ELISA: P7M peptide containing His and Arg had greater reactivity and this reactivity was dramatically decreased when positively charged His and Arg were transformed to the aliphatic side-chain Leu in P7M-m1 and P7M-m2, respectively (Fig. 5) . Mutational analysis of the epitope showed that a single amino acid change within this peptide affected antibody-binding activity dramatically. His and Arg are important for Ab4 binding, confirming further that charged residues are important in antigenic epitope-antibody interactions (Strauss et al., 1991; Wu et al., 2001a) . (Vaughn et al., 1998 (Vaughn et al., , 1999 Lam & Devine, 1998) . Therefore, it is necessary to develop specific diagnostic reagents for DEN serotyping. DHF and DSS have been associated strongly with sequential infections by different DEN serotypes. It has been hypothesized that non-neutralizing crossreactive antibodies acquired during the first DEN infection enhance the second infection by a different DEN serotype (Halstead, 1988) . The molecular mechanism underlying this explanation has not been determined because serotypespecific peptide antigens that distinguish the four serotypes DEN infection have not been isolated and identified.
The similarity of amino acid sequences for the four DEN serotypes ranges from 63?2 to 78?7 % (Westaway & Blok, 1997) . High similarity of amino acid sequences within the four DEN serotypes makes them difficult to distinguish using antigens obtained from overlapping synthetic peptides (PEPSCAN) or from recombinant or enzyme-cleavage antigen fragments. Generation of serotype-specific mAbs against DEN and investigation of B-cell epitopes makes it possible to identify serotype-specific epitopes and to develop epitope-based peptides for the diagnosis of DEN infection (Wu et al., 2001a) . In this study, we identified the serotype-specific epitope of DEN-2 and used an epitopebased peptide as an antigen to detect DEN-2 antibodies in serum samples from immunized mice and rabbits. Applications of this epitope-based peptide to human serum samples are in progress. Specifically, we are evaluating whether it can distinguish the four DEN serotypes and determine whether a DEN infection is primary or secondary. Using a synthetic peptide for DEN diagnosis is relatively simple and should become routine. Because a second infection with a different DEN serotype increases the risk for DHF and DSS, serotype identification is important. At present, neither a protein nor a peptide antigen is being used to differentiate the four serotypes of DEN or JEV infection. We believe that a serotype-specific mAb and the epitope-based peptide of DEN-2 will be valuable for developing a serotype-specific diagnostic reagent.
